BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)
NCT03771885 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2021-11-15
Summary
The main objective of this study is to assess the safety, tolerability and pharmacokinetics of orally administered BI 705564 in patients with systemic lupus erythematosus
Conditions
- Lupus Erythematosus, Systemic
Interventions
- DRUG
-
BI 705564
Film-coated Tablet
- DRUG
-
Film-coated Tablet
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-16
- Primary Completion
- 2019-12-21
- Completion
- 2020-01-07
More Related Trials
-
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
NCT00410384 ·Status: COMPLETED ·Phase: PHASE3
-
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
NCT02770170 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04895241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
NCT04925934 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
NCT00071487 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
NCT01085084 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
NCT00657007 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
NCT02708095 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
NCT03616964 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02446899 ·Status: COMPLETED ·Phase: PHASE3
-
BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
NCT01499355 ·Status: TERMINATED ·Phase: PHASE2
-
ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
NCT02955615 ·Status: COMPLETED ·Phase: PHASE2
-
Study of M5049 in CLE and SLE Participants
NCT04647708 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
NCT01689025 ·Status: TERMINATED ·Phase: PHASE1
-
Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients
NCT02331810 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
NCT03616912 ·Status: TERMINATED ·Phase: PHASE3
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285 ·Status: RECRUITING
-
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
NCT02265744 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01196091 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
NCT00732940 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
NCT07299422 ·Status: RECRUITING ·Phase: PHASE2
-
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
NCT06161116 ·Status: TERMINATED ·Phase: PHASE2